CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka-Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung
Korean J Intern Med. 2019;34(6):1333-1346.   Published online 2018 October 26    DOI: https://doi.org/10.3904/kjim.2018.144

Excel Download

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
The Korean Journal of Internal Medicine. 2019;34(6):1333-1346   Crossref logo
Link1 Link2 Link3

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
Yearbook of Oncology. 2009;2009:121-122   Crossref logo
Link1 Link2

Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Lymphoma Myeloma and Leukemia. 2017;17(1):e26-e27   Crossref logo
Link1 Link2

MELPHALAN PLUS PREDNISONE AGAINST PLASMA-CELL MYELOMA
InPharma. 1979;211(1):9-9   Crossref logo
Link1 Link2 Link3

PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES
Value in Health. 2011;14(3):A62   Crossref logo
Link1 Link2

Immortal time bias and reverse causality in retrospective analysis: Comment on “effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study”
American Journal of Hematology. 2015;90(8):E146-E146   Crossref logo
Link1

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
European Journal of Haematology. 2001;66(5):328-336   Crossref logo
Link1

Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III
European Journal of Cancer and Clinical Oncology. 1991;27:S51-S52   Crossref logo
Link1 Link2

PSY32 THALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOR AUSTRALIAN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA IS COST-EFFECTIVE WHEN COMPARED WITH MELPHALAN AND PREDNISONE ALONE
Value in Health. 2009;12(7):A381   Crossref logo
Link1 Link2

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Yearbook of Oncology. 2010;2010:144-146   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Korean J Intern Med has participated in CrossRef Text and Data Mining service since August 31, 2015.